Other Significant Agreements - Paragon Agreement (Details) $ in Thousands			1 Months Ended		3 Months Ended					6 Months Ended
		Aug. 12, 2024 USD ($)	Nov. 30, 2023 USD ($)	Nov. 30, 2022 USD ($) Item shares	Jun. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) shares	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)
Other Significant Agreements Paragon Option Agreement
Research and development	[1]				$ 33,206				$ 13,946	$ 61,922	$ 22,401
Issued total common units (in shares) | shares					58,481,214		50,655,671			58,481,214
Option Agreement
Other Significant Agreements Paragon Option Agreement
Aggregate acquisition cost				$ 3,500
Paragon Therapeutics, Inc | Related party
Other Significant Agreements Paragon Option Agreement
Research and development					$ 2,200				$ 5,900	$ 8,700	$ 13,400
Paragon Therapeutics, Inc | Option Agreement
Other Significant Agreements Paragon Option Agreement
Payments due upon exercise of option				$ 0
Termination period of agreement			30 days	30 days
Period of material breach			30 days	30 days
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice			30 days	30 days
Payment of non-refundable fees						$ 2,000
Paragon Therapeutics, Inc | Option Agreement | Related party
Other Significant Agreements Paragon Option Agreement
Number of selected targets initially included under the agreement | Item				2
Upfront cash amount paid				$ 1,300
Issued common units (in shares) | shares				1,250,000
Issued total common units (in shares) | shares				5,000,000
Aggregate fair value on grant date				$ 2,200
Non-refundable fee			$ 2,000	$ 500
Paragon Therapeutics, Inc | Option Agreement | Maximum | Related party
Other Significant Agreements Paragon Option Agreement
Issued total common units (in shares) | shares				3,750,000
Paragon Therapeutics, Inc | Paragon IL13 License Agreement
Other Significant Agreements Paragon Option Agreement
Expiration period of commercial sale				12 years
Termination period of agreement				60 days
Period of material breach				90 days
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice				30 days
Paragon Therapeutics, Inc | Paragon IL13 License Agreement | Related party
Other Significant Agreements Paragon Option Agreement
Maximum amount of achievement of development and clinical mile stones				$ 3,000
Nomination fee paid				1,000	$ 1,000	$ 2,000	$ 1,000	$ 2,000
Milestone payment of trial payable				$ 2,000
Paragon Therapeutics, Inc | TSLP License Agreement | Subsequent Event
Other Significant Agreements Paragon Option Agreement
Expiration period of commercial sale		12 years
Termination period of agreement		60 days
Period of material breach		90 days
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice		30 days
Paragon Therapeutics, Inc | TSLP License Agreement | Related party | Subsequent Event
Other Significant Agreements Paragon Option Agreement
Maximum amount of achievement of development and clinical mile stones		$ 28,000
Nomination fee paid		3,000
Milestone payment of trial payable		$ 5,000

[1] Includes related-party amounts of $2,221 and $8,678 for the three and six months ended June 30, 2024, respectively, and $5,884 and $13,411 for the three and six months ended June 30, 2023, respectively.